atopic eczema eczema
Conditions
Interventions
None listed
Sponsors
MedImmune Biotech
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: * adults (*18 years of age);and for: * group a (n
Exclusion criteria
Exclusion criteria: * on systemic therapy at time of recruitment * previous receipt of any investigational agent within 4 weeks prior to recruitment or within 5 half-lives of the investigational agent, whichever is longer *evidence of other skin conditions, including, but not limited to, T-cell lymphoma or allergic contact dermatitis *not willing to be biopsied;group d: a history of AD, allergic rhinitis or asthma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - The presence of a molecular signature of disease exacerbation in the skin and peripheral blood of patients with moderate to severe atopic dermatitis will be assessed using the following parameters: - Composite scores for disease activity and treatment response and patient reported outcome measures (PROMS): o The Six Area, Six Sign Atopic Dermatitis (SASSAD) o SCORing AD (SCORAD) o Eczema Area and Severity Index (EASI) o Investigator Global Assesment (IGA) o Patient Oriented Eczema Measure (POEM) o Self-assessed EASI (SA-EASI) - Biomarkers measured in serum and DBS (Luminex: panel of biomarkers including TARC, MDC, PARC, IL-22, sE-selectin, sIL-2R and IL-16 based on our previous findings and somalogics: http://www.somalogic.com/) - Molecular analysis of gene expression from peripheral blood mononuclear cells (PBMC) - Molecular analysis of gene expression from skin biopsies - Immunohistochemistry skin biopsies | — |
Secondary
| Measure | Time frame |
|---|---|
| *Define the propensity of S. aureus colonization/infection of patients and association with disease exacerbation *Define the association with asthma and how severity of atopic dermatitis correlates with asthma severity | — |
Countries
Netherlands
Outcome results
None listed